Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.

摘要: It is well established that visceral leishmaniasis (VL; also known as Kala azar) causes immunosuppression, and a successful drug treatment associated with the development of cell-mediated immunity. Therefore combining an immune enhancer can provide better approach for disease. Keeping this in mind, vivo antileishmanial efficacy immunochemotherapy was evaluated use 78 kDa antigen or without monophosphoryl lipid A (MPL-A) along traditional sodium stibogluconate (SSG) Leishmania donovani infected BALB/c mice. Mice were intracardially promastigotes L. donovani, 30 days after infection, these animals given specific immunotherapy (78 kDa/78 kDa+MPL-A) chemotherapy (SSG+78 kDa/SSG+78 kDa+MPL-A). Animals euthanased on 1, 15 post-treatment days. The potential revealed by significant reduction parasite burden (P<0·001). These found to exhibit increased delayed type hypersensitivity (DTH) responses, higher IgG2a levels, lower IgG1 levels greater cytokine (IFN-γ IL-2) concentrations compared alone, pointing towards generation strong protective (Th1) response. Immunochemotherapy SSG+78 kDa+MPL-A be most effective protecting mice against VL therefore alternative option VL.